Levels of Molecular Intelligence^™ Service

Our suite of tumor profiling services allows the physician to customize the level of profiling they deem necessary for each patient.

Learn more about the multiple cancer profiling technologies we use or visit CarisMolecularIntelligence.com for more information.

Molecular Intelligence^™ Service, from Caris Life Sciences^®, provides evidence-based tumor information that associates biomarker status to agents with potential clinical benefit or potential lack of clinical benefit. Agents associated with clinical benefit are presented based on NCCN Compendium^™ inclusion, relevance of tumor type, level of published evidence and strength of biomarker expression. Report information must be considered in conjunction with all other relevant information in respect of a given patient before determining the appropriate course of treatment. The selection of agents for re-treatment from prior chemotherapy regimens lies with the treating physician and must be done with careful consideration. Caris Molecular Intelligence Service was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. Caris Molecular Intelligence Service has not been approved by the United States Food and Drug Administration.